Management of bone metastases in refractory prostate cancer – role of denosumab

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statisticsCA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• de BonoJSOudardSOzgurogluMfor TROPIC InvestigatorsPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• BubendorfLSchopferAWagnerUMetastatic patterns of prostate cancer: an autopsy study of 1,589 patientsHum Pathol200031557858310836297
   PubMed Web of Science ®Google Scholar
• ScherHIMorrisMJBaschEHellerGEnd points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practiceJ Clin Oncol201129273695370421859988
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMDe BonoJSInterim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [abstract]J Clin Oncol201230SupplLBA4518
   Google Scholar
• ParkerCHeinrichDO’SullivanJOverall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract]J Clin Oncol2012Suppl 58
   Web of Science ®Google Scholar
• De BonoJSFizaziKSaadFPrimary, secondary and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor [abstract]J Clin Oncol201230Suppl4519
   Google Scholar
• SmithMRKabbinavarFSaadFNatural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancerJ Clin Oncol200523132918292515860850
   PubMed Web of Science ®Google Scholar
• SmithMRCookRLeeKANelsonJBDisease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancerCancer2011117102077208521523719
   PubMed Web of Science ®Google Scholar
• SmithMRSaadFColemanRDenosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialLancet20123799810394622093187
   PubMed Web of Science ®Google Scholar
• FizaziKCarducciMSmithMDenosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyLancet2011377976881382221353695
   PubMed Web of Science ®Google Scholar
• RoodmanGDMechanisms of bone metastasisN Engl J Med2004350161655166415084698
   PubMed Web of Science ®Google Scholar
• VenkitaramanRSohaibSABarbachanoYDetection of occult spinal cord compression with magnetic resonance imaging of the spineClin Oncol (R Coll Radiol)200719752853117499490
   PubMed Web of Science ®Google Scholar
• Even-SapirEMetserUMishaniELievshitzGLermanHLeibovitchIThe detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CTJ Nucl Med200647228729716455635
   PubMed Web of Science ®Google Scholar
• BlairHCTeitelbaumSLGhiselliRGluckSOsteoblastic bone resorption by a polarized vacuolar proton pumpScience198924549208558572528207
   PubMed Web of Science ®Google Scholar
• BrownJECookRJMajorPBone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumorsJ Natl Cancer Inst2005971596915632381
   PubMed Web of Science ®Google Scholar
• SmithMRSaadFEgerdieBDenosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancerJ Bone Miner Res201126122827283321898590
   PubMed Web of Science ®Google Scholar
• PallerCJShielsMSRohrmannSRelationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of menClin Endocrinol (Oxf)2009701263418485120
   PubMed Web of Science ®Google Scholar
• GennariLNutiRBilezikianJPAromatase activity and bone homeostasis in menJ Clin Endocrinol Metab200489125898590715579733
   PubMed Web of Science ®Google Scholar
• SmithMRMcGovernFJZietmanALPamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancerN Engl J Med20013451394895511575286
   PubMed Web of Science ®Google Scholar
• ShahinianVBKuoYFFreemanJLGoodwinJSRisk of fracture after androgen deprivation for prostate cancerN Engl J Med2005352215416415647578
   PubMed Web of Science ®Google Scholar
• SaylorPJMortonRAHancockMLBarnetteKGSteinerMSSmithMRFactors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancerJ Urol2011186248248621679977
   PubMed Web of Science ®Google Scholar
• AlibhaiSMDuong-HuaMCheungAMFracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 menJ Urol2010184391892320643458
   PubMed Web of Science ®Google Scholar
• JonesCUHuntDMcGowanDGRadiotherapy and short-term androgen deprivation for localized prostate cancerN Engl J Med2011365210711821751904
   PubMed Web of Science ®Google Scholar
• BollaMde ReijkeTMVan TienhovenGfor EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer GroupDuration of androgen suppression in the treatment of prostate cancerN Engl J Med2009360242516252719516032
   PubMed Web of Science ®Google Scholar
• MessingEMManolaJSarosdyMWildingGCrawfordEDTrumpDImmediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancerN Engl J Med1999341241781178810588962
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRfor TAX 327 InvestigatorsDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaAfor COU-AA-301 InvestigatorsAbiraterone and increased survival in metastatic prostate cancerN Engl J Med2011364211995200521612468
   PubMed Web of Science ®Google Scholar
• CarducciMASaadFAbrahamssonPAfor Atrasentan Phase III Study Group InstitutionsA phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancerCancer200711091959196617886253
   PubMed Web of Science ®Google Scholar
• NelsonJBFizaziKMillerKPhase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration resistant prostate cancer (CRPC) [abstract]J Clin Oncol201129Suppl 7117
   Web of Science ®Google Scholar
• YuEYMassardCGrossMEOnce-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancerUrology201177511661171
   Google Scholar
• SartorOOverview of samarium sm 153 lexidronam in the treatment of painful metastatic bone diseaseRev Urol20046Suppl 10S31216985930
   PubMedGoogle Scholar
• DearnaleyDPMasonMDParmarMKSandersKSydesMRAdjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trialsLancet Oncol200910987287619674936
   PubMed Web of Science ®Google Scholar
• MichaelsonMDKaufmanDSLeeHRandomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancerJ Clin Oncol20072591038104217369566
   PubMed Web of Science ®Google Scholar
• GreenspanSLNelsonJBTrumpDLResnickNMEffect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trialAnn Intern Med2007146641642417371886
   PubMed Web of Science ®Google Scholar
• SmallEJSmithMRSeamanJJPetroneSKowalskiMOCombined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancerJ Clin Oncol200321234277428414581438
   PubMed Web of Science ®Google Scholar
• SaadFGleasonDMMurrayRfor Zoledronic Acid Prostate Cancer Study GroupA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
   PubMed Web of Science ®Google Scholar
• KostenuikPJNguyenHQMcCabeJDenosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKLJ Bone Miner Res200924218219519016581
   PubMed Web of Science ®Google Scholar
• AmgenXGEVA (denosumab) Injection, for Subcutaneous Use: US Prescribing Information [document on the Internet]Thousand Oaks, CAAmgen [updated 2011]. Available from: http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdfAccessed on May 2, 2012
   Google Scholar
• FizaziKLiptonAMarietteXRandomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonatesJ Clin Oncol200927101564157119237632
   PubMed Web of Science ®Google Scholar
• HenryDHCostaLGoldwasserFRandomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myelomaJ Clin Oncol20112991125113221343556
   PubMed Web of Science ®Google Scholar
• LewieckiEMBilezikianJPDenosumab for the treatment of osteoporosis and cancer-related conditionsClin Pharmacol Ther201291112313322158568
   PubMed Web of Science ®Google Scholar
• SeemanEDelmasPDHanleyDAMicroarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronateJ Bone Miner Res20102581886189420222106
   PubMed Web of Science ®Google Scholar
• StopeckATLiptonABodyJJDenosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyJ Clin Oncol201028355132513921060033
   PubMed Web of Science ®Google Scholar
• LiptonAStegerGGFigueroaJRandomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastasesJ Clin Oncol200725284431443717785705
   PubMed Web of Science ®Google Scholar
• BodyJJFaconTColemanREA study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancerClin Cancer Res20061241221122816489077
   PubMed Web of Science ®Google Scholar
• ColemanRERisks and benefits of bisphosphonatesBr J Cancer200898111736174018506174
   PubMed Web of Science ®Google Scholar
• LiptonAStegerGGFigueroaJExtended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapyClin Cancer Res200814206690669618927312
   PubMed Web of Science ®Google Scholar
• Amgen IncorporatedProlia™ (Denosumab) injection, for subcutaneous use: US prescribing information [online]Thousand Oaks, CAAmgen Inc2010 http://pi.amgen.com/united_states/prolia/prolia_pi.pdfAccessed May 1, 2012
   Google Scholar
• Amgen IncorporatedXGEVA (denosumab) injection, for subcutaneous use: US prescribing information [online]Thousand Oaks, CAAmgen Inc2010 http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdfAccessed May 1, 2012
   Google Scholar
• Amgen IncorporatedProlia 60 mg Solution for Injection in a Prefilled Syringe: EU Summary of Product CharacteristicsBreda, The NetherlandsAmgen Europe BV2010
   Google Scholar
• BekkerPJHollowayDLRasmussenASA single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal womenJ Bone Miner Res20041971059106615176987
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRfor FREEDOM TrialDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• SmithMREgerdieBHernandez TorizNfor Denosumab HALT Prostate Cancer Study GroupDenosumab in men receiving androgen-deprivation therapy for prostate cancerN Engl J Med2009361874575519671656
   PubMed Web of Science ®Google Scholar
• AdlerRAGillRSClinical utility of denosumab for treatment of bone loss in men and womenClin Interv Aging2011611912421753866
   PubMed Web of Science ®Google Scholar
• National Osteoperosis FoundationClinician’s Guide to Prevention and Treatment of OsteoporosisWashington, DCNational Osteoporosis Foundation2010
   Google Scholar
• RothsteinADenosumab Safety: Division of Reproductive and Urologic Products, Center of Drug Evaluation and Research at the Food and Drug Administration [document on the Internet]; [updated 2009]. Available from: http://courses.washington.edu/bonephys/denosumab/Rothstein%20FDA%20deno%20safety.pdfAccessed on May 2, 2012
   Google Scholar
• ShoreNSmithRJievaltasMEffect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: subgroup analyses by prior SRE and baseline painJ Clin Oncol201129Suppl4533
   Google Scholar
• BodyJJLiptonAGralowJEffects of denosumab in patients with bone metastases with and without previous bisphosphonate exposureJ Bone Miner Res201025344044619653815
   PubMed Web of Science ®Google Scholar
• HaleCODAC votes to nix Amgen’s drug Xgeva for proposed prostate cancer indicationCancer Lett20123871
   Google Scholar
• GoldbergPXgeva doesn’t meet the bar in controversial indicationCancer Lett201238188
   Google Scholar
• MasonMDSydesMRGlaholmJfor Medical Research Council PR04 CollaboratorsOral sodium clodronate for nonmetastatic prostate cancer – results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)J Natl Cancer Inst2007991076577617505072
   PubMedGoogle Scholar
• NelsonJBLoveWChinJLfor Atrasentan Phase 3 Study GroupPhase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancerCancer200811392478248718785254
   PubMed Web of Science ®Google Scholar
• LeeRJSmithMROsteoclast-targeted therapy for metastatic prostate cancerTherapy2008516372
   Google Scholar
• SnedecorSJCarterJAKauraSBottemanMCost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal- related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC)J Clin Oncol201129Suppl458122025158
   PubMed Web of Science ®Google Scholar
• XieJNamjoshiMWuEQEconomic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastasesJ Manag Care Pharm201117862164321942303
   PubMed Web of Science ®Google Scholar
• GyrtaTAmgen’s Xgeva hits resistance over cost-benefit debate [article on the Internet]New YorkDow Jones News Service [updated April 5, 2011; cited February 18, 2012]. Available from: http://www.advfn.com/news_Amgens-Xgeva-Hits-Resistance-Over-Cost-Benefit-Debate_47174840.htmlAccessed February 18, 2012522012
   Google Scholar
• GibianskyLSutjandraLDoshiSPopulation pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumoursClin Pharmacokinet201251424726022420579
   PubMedGoogle Scholar
• EMCXGEVA pharmacological properties [homepage on the Internet]CambridgeMedicines Compendium [updated 2012]. Available from: http://www.medicines.org.uk/emc/medicine/24755/SPC/xgeva/Accessed on May 2, 2012
   Google Scholar